Novo Nordisk A/S (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 78   

Articles published

NVO 45.24 +0.19 (0.42%)
price chart
McDonald's Corporation (MCD), Novo Nordisk A/S (ADR) (NVO), Colgate ...
Novo Nordisk A/S (ADR) (NYSE:NVO) also kept its spot in Mr. Simons' list. The $189 billion market cap healthcare company witnessed a 5% boost in the fund's exposure between April and June.
Stocks to Track - Novo Nordisk A/S (ADR) (NYSE:NVO), BioScrip Inc (NASDAQ ...
Birmingham, West Midlands - (TechSonian) �Aug 09, 2014 - Novo Nordisk A/S (ADR) (NYSE:NVO) involves in the discovery, development, manufacture, and marketing of pharmaceutical products primarily in Denmark.
Related articles »  
Novo Nordisk Drops 2% On Lower Net Income Guidance
Novo Nordisk A/S (ADR) (NVO) announced second-quarter earnings yesterday for fiscal'14 (2QFY14). The Danish pharmaceutical company reported revenues of $3.87 billion (21.6 billion kroner), up 1% year-over-year (YoY), against the Street's sales ...
Related articles »  
Morning Buzz : Novo Nordisk A/S (NYSE:NVO), Bally Technologies (NYSE:BYI ...
On 1 May 2014, Novo Nordisk A/S (NYSE:NVO) initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.
Novo Nordisk A/S's "Neutral" Rating Reaffirmed at Zacks (NVO)
Zacks' analyst wrote, �Novo Nordisk reported second-quarter 2014 earnings of $0.48 per ADR, higher than the year-ago earnings of 44 cents.
Novo Nordisk A/S: Share repurchase programme
Headquartered in Denmark, Novo Nordisk employs approximately. 40,700 employees in 75 countries, and markets its products in more than 180 countries.
Related articles »  
Novo Nordisk A/S Receives Neutral Rating from Zacks (NVO)
Novo Nordisk A/S logo Zacks reaffirmed their neutral rating on shares of Novo Nordisk A/S (NYSE:NVO) in a research note issued to investors on Wednesday.
Novo Nordisk A/S Rating Reiterated by Zacks (NVO)
Zacks' analyst wrote, �Novo Nordisk reported first-quarter 2014 earnings of $0.45 per ADR, a penny above the Zacks Consensus Estimate of $0.44.
Related articles »  
Intercept Could Soon Be The Market Leader For Obesity Treatment
Other competitors with similar projects in their pipelines include Gilead Sciences, Inc. (GILD) and Novo Nordisk A/S (ADR) (NVO). Gilead's monoclonal antibody, Simtuzumab, has reached the second phase of trials, while Novo Nordisk's weight loss ...
Related articles »  
Hot Stock List: Halliburton Company (NYSE:HAL), CBOE (NASDAQ:CBOE ...
Novo Nordisk A/S (NYSE:NVO) on 8 August reported second-quarter 2014 earnings of 48 cents per American Depository Receipt (:ADR), higher than the year-ago earnings of 44 cents. In the reported quarter, revenues increased 6% to $3.9 billion year over ...